Form 4: BioCryst Pharmaceuticals Director Nancy Hutson Receives Automatic Equity Grants

BioCryst Pharmaceuticals, Inc. Director Nancy J. Hutson was granted 12,500 Restricted Stock Units and 27,181 stock options as part of the company's non-employee director compensation policy.

Summary

• Nancy J. Hutson, a Director of BioCryst Pharmaceuticals, Inc. (BCRX), received an automatic grant of equity securities.
• On June 12, 2025, she was granted 12,500 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 and are scheduled to vest on the first anniversary of the grant date, which is June 12, 2026.
• Following this transaction, her direct beneficial ownership of Common Stock is 99,138 shares.
• Additionally, on June 12, 2025, she received an automatic grant of 27,181 stock options.
• These stock options have an exercise price of $10.4 and were granted at a price of $0.
• The stock options become exercisable on June 12, 2026, and are set to expire on June 12, 2035.
• Her direct beneficial ownership of derivative securities (stock options) is 27,181.
• Both grants were made pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.
• A Power of Attorney dated June 11, 2025, was executed by Nancy Hutson, appointing Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports, including Forms 3, 4, and 5, on her behalf.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. It details routine director compensation, which is a standard practice aligning director interests with shareholders. There are no negative surprises or significant positive catalysts, making it a generally expected and stable disclosure.

Positives

• The grants align with the company's established Non-Employee Director Compensation Policy, indicating consistent corporate governance practices.
• Equity grants to directors align their interests with long-term shareholder value, incentivizing performance tied to the company's stock.

Future Outlook

The granted Restricted Stock Units are set to vest on June 12, 2026, and the stock options will become exercisable on the same date, expiring on June 12, 2035. These future dates represent the timeline for the director's equity compensation.

Management Comments

• "The undersigned hereby constitutes and appoints each of Alane P. Barnes and Sara A. Mykrantz, signing singly and not jointly, with full power of substitution, as the undersigneds true and lawful attorney-in-fact..." (from Power of Attorney, signed by Nancy Hutson)
• "The undersigned acknowledges that such attorneys-in-fact, in serving in such capacity at the request of the undersigned, do not assume any of the undersigned's responsibilities to comply with the Exchange Act or any rule or regulation of the SEC." (from Power of Attorney, signed by Nancy Hutson)

Industry Context

This filing represents a routine director compensation event, common across publicly traded companies. Equity grants are a standard practice to align the interests of non-employee directors with shareholders, encouraging long-term value creation. It does not indicate any specific industry-wide trends or competitive shifts.

Comparison to Industry Standards

• The automatic grant of Restricted Stock Units and stock options to a non-employee director, pursuant to a pre-defined compensation policy, is a standard practice in the biotechnology and pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize similar equity-based compensation structures for their non-executive directors to incentivize long-term performance and align interests with shareholders.
• The specific amounts and vesting schedules are typical for director compensation packages, reflecting a balance between attracting qualified board members and managing equity dilution.

Corporate Governance

Related Party Transactions

• The grants of Restricted Stock Units and stock options to Director Nancy Hutson constitute related party transactions, as they are compensation provided by the company to a member of its board. These are disclosed as part of the company's Non-Employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The grants align director interests with long-term shareholder value, as the value of the equity compensation is tied to the company's stock performance. However, it also represents a minor potential dilution of existing shares over time as RSUs vest and options are exercised.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 12,500 Restricted Stock Units will vest on June 12, 2026.
• The 27,181 stock options will become exercisable on June 12, 2026.
• The Power of Attorney will remain in effect until Nancy Hutson is no longer required to file Section 16 Filings, unless earlier revoked.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, SEC Form 4, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Insider Transaction, Corporate Governance, Nancy Hutson